Virtual Library
Start Your Search
F. Chen
Author of
-
+
P1.02 - Poster Session with Presenters Present (ID 454)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Biology/Pathology
- Presentations: 1
- Moderators:
- Coordinates: 12/05/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P1.02-068 - The Impact of TP53 Overexpression on EMT and the Prognosis in Lung Adenocarcinoma Harboring Driver Mutations (ID 4489)
14:30 - 15:45 | Author(s): F. Chen
- Abstract
Background:
Epithelial-mesenchymal transition (EMT) and p53 mutations are known to be pivotal for driving metastasis and recurrence in lung cancer, but the nature of these factors is not completely understood. Some papers have previously described the relationship between EMT and TP53 in other carcinomas, however there have been few reports about the impact of TP53 on EMT and prognosis in lung adenocarcinoma harboring driver mutations such as EGFR or K-ras.
Methods:
The aim of the present study is to clarify the impact of TP53 overexpression in lung adenocarcinoma with driver mutations. A total of 282 lung adenocarcinoma specimens were collected from patients who had undergone surgery in our institute from January 2001 to December 2007. Both EMT markers (E-cadherin, vimentin) and TP53 were analyzed through immunostaining of tumor specimens. The association between EMT and TP53 as well as the patients’ clinical information was integrated and statistically analyzed. EGFR and K-ras mutation were determined by single stranded conformational polymorphism and direct sequencing. Correlations were compared using Pearson's chi-square test and overall survival were compared using the log-rank test.
Results:
Both mesenchymal type (E-cadherin negative, vimentin positive) and TP53 overexpression were significantly correlated with poor prognosis (P=0.0001, P=0.0019). A positive correlation was found between EMT activation level and TP53 overexpression (P=0.017). TP53 overexpression was significantly correlated with poor prognosis in the subgroup of lung adenocarcinoma with driver mutation (EGFR or K-ras) (P=0.011, P=0.026), whereas there was no significant correlation between TP53 overexpression and the prognosis in adenocarcinoma without driver mutations (P=0.359).
Conclusion:
TP53 overexpression is supposed to be the key factor that affects EMT and the prognosis, and also might be an additional therapeutic target for lung adenocarcinoma with driver mutations.
-
+
P2.04 - Poster Session with Presenters Present (ID 466)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Mesothelioma/Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies
- Presentations: 1
- Moderators:
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.04-012 - A Risk of Death from a Second Cancer Following Complete Resection of Thymoma (ID 4217)
14:30 - 15:45 | Author(s): F. Chen
- Abstract
Background:
A portion of patients undergoing complete resection of thymoma develop recurrence of thymoma, while those undergoing thymectomy for thymoma are at risk of developing a second cancer, but it remains unknown whether those patients are more at risk of death from thymoma or from a second cancer.
Methods:
Retrospective chart review was performed on our prospectively maintained database of patients undergoing complete resection of thymoma at our institution between 1991 and 2016. Thymoma-specific survival was calculated from thymectomy to death of recurreence of thymoma. Second cancer-specific survival was calculated from thymectomy to death of a second cancer. Both were estimated with Kaplan-Meier method.
Results:
Follow-up ranged from 1 to 239 months (median: 54). One hundred and sixty-four patients were identified. During the follow-up, there were four thymoma deaths and 4 deaths from a second cancer. Five-year and 10-year thymoma specific survival was 97.8% and 96.1%, respectively. Five-year and 10-year second cancer specific survival was 98.2% and 96.1%, respectively.
Conclusion:
It appears that patients undergoing thymectomy for thymoma are at a similar risk of a second cancer death to that of thymoma death. However, there are too few events during the follow-up and a multi-institutional database is required to more rigorously evaluate both risks.
